Wu 2002

Methods	Randomised, double‐blind multicentre trial. Random number generation done centrally, double‐blinded by use of identical placebos. Allocation concealment achieved by sealed, sequentially‐numbered, tinted bottles filled and labelled by manufacturer
Participants	903 healthy women recruited in the study from 10 clinics in Shanghai, China Included women with regular menstrual periods (22‐42 days), who had a single act of unprotected intercourse within 120 h of attending the clinic and they were willing to avoid further acts of unprotected coitus during that cycle and willing to have an induced abortion if pregnancy was diagnosed following intake of the study drug during the study period Excluded women with current pregnancy or breastfeeding, on hormonal contraception in the current cycle and those with uncertain dates of last menstrual period
Interventions	Mife 25 mg, 24 h later misoprostol 0.2 mg vs Mife 10 mg, 24 h later misoprostol 0.2 mg vs Mife (single dose) 10 mg + placebo
Outcomes	Observed number of pregnancies, side effects and changes in menstrual pattern
Notes	Loss to follow‐up: total 3 cases, 1 case protocol violation Observed pregnancy/expected pregnancy/total number of women: Mife 25 mg + misoprostol 2/22/300; Mife 10 mg + misoprostol 2/21/299; Mife 10 mg + placebo 7/22/300
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number generation done centrally
Allocation concealment (selection bias)	Low risk	Allocation concealment achieved by sealed, sequentially‐numbered, tinted bottles, filled and labelled by manufacturer
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Post‐randomisation exclusion and loss to follow‐up reported
Selective reporting (reporting bias)	Low risk	Reported planned outcomes
Other bias	Low risk	None detected